This interactive case-based symposium will highlight contemporary controversies in MS disease management. Three debates will be moderated by the symposium chairs around the following questions: 1) Does early MS treatment prevent future disability, 2) Is rituximab an acceptable MS therapy alternative for the newer B-cell therapies, and 3) Can therapies approved for active secondary progressive MS be used for inactive secondary progressive MS. The speakers in this symposium are seasoned MS clinicians and will be presented with a clinical case to debate and make their points. Questions from the audience will be encouraged and integrated into this symposium.
[learn_press_profile]